Enhanced CAR T-cell Therapy Shows Promise in Early Trial for B-cell Cancers

A Phase I clinical trial led by The Ohio State University Comprehensive Cancer Center has demonstrated early potential for an enhanced CAR T-cell therapy in treating relapsed or treatment-resistant B-cell blood cancers. These findings, published in Blood Cancer Discovery, suggest a possible improvement in therapeutic options for affected patients.

Originally published by gnews